Table 1.
Baseline demographics and clinical characteristics
| No of patients | 55 |
| Age, median, years | 66.3 |
| Range, years | 52–80 |
| Characteristics | No of patients (%) |
| TPSA (µg/L) | |
| <4 | 17 (30.9) |
| 4–10 | 15 (27.3) |
| 10–20 | 7 (12.7) |
| >20 | 16 (29.1) |
| FPSA (µg/L) | |
| 0–1 | 31 (56.4) |
| >1 | 24 (43.6) |
| F/T | |
| 0–0.25 | 44 (80.0) |
| 0.25–1 | 9 (16.4) |
| >1 | 2 (3.6) |
| Gleason sum score | |
| 6 | 6 (10.9) |
| 7 | 21 (38.2) |
| 8 | 10 (18.2) |
| 9 | 17 (30.9) |
| 10 | 1 (1.82) |
| Disease status | |
| cT | |
| T1 | 6 (10.9) |
| T2a | 1 (1.82) |
| T2b | 17 (30.9) |
| T2c | 8 (14.5) |
| T3a | 6 (10.9) |
| T3b | 15 (27.3) |
| T4 | 2 (3.64) |
| N | |
| N0 | 38 (69.1) |
| N1 | 17 (30.9) |
| M | |
| M0 | 39 (70.9) |
| M1 | 16 (29.1) |
| Stage | |
| I | 2 (3.64) |
| IIA | 3 (5.45) |
| IIB | 5 (9.09) |
| IIC | 1 (1.82) |
| IIIA | 6 (10.9) |
| IIIB | 7 (12.7) |
| IVA | 3 (5.45) |
| IVB | 28 (50.9) |
| Surgical margin status | |
| Positive | 20 (36.4) |
| Negative | 35 (63.6) |
cT, clinical T; FPSA, free prostate-specific antigen; TPSA, total prostate-specific antigen.